PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00038311
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2010-02-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 111
- Registration Number
- NCT00038103
- Locations
- 🇵🇭
Pfizer Investigational Site, Manila, Philippines
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
Phase 1
Completed
- Conditions
- First Posted Date
- 2002-05-22
- Last Posted Date
- 2009-08-14
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00037804
- Locations
- 🇺🇸
Research Center, Marshfield, Wisconsin, United States
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-22
- Last Posted Date
- 2006-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 180
- Registration Number
- NCT00037791
- Locations
- 🇲🇽
Pfizer Investigational Site, Mexico City, DF, Mexico
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00037219
- Locations
- 🇺🇸
Versicor, Inc., King of Prussia, Pennsylvania, United States
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00037206
- Locations
- 🇺🇸
Versicor, Inc., King of Prussia, Pennsylvania, United States
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
Phase 2
Terminated
- Conditions
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 212
- Registration Number
- NCT00037180
- Locations
- 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-15
- Last Posted Date
- 2009-09-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 739
- Registration Number
- NCT00037050
Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
Phase 1
Completed
- Conditions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00036140
- Locations
- 🇺🇸
Research Center, Marshfield, Wisconsin, United States
Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease
Phase 3
Terminated
- Conditions
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2007-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 984
- Registration Number
- NCT00036205
- Locations
- 🇵🇷
Pfizer Investigational Site, Carolina, Puerto Rico
© Copyright 2024. All Rights Reserved by MedPath